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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
hydroxyanthracene derivatives and improvement of bowel function 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Vivatech, submitted for authorisation of a health claim pursuant to Article 13(5) 
of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to hydroxyanthracene derivatives and improvement of bowel function. An improvement of bowel function 
such as reduced transit time, more frequent bowel movements, increased faecal bulk, or softer stools is a 
beneficial physiological effect, provided that it does not result in diarrhoea. The Panel notes that the effect of 
hydroxyanthracene derivatives from the root and rhizome of Rheum palmatum L. and/or Rheum officinale 
Baillon and/or their hybrids, from the leaves or fruits of Cassia senna L. and/or Cassia angustifolia Vahl, from 
the bark of Rhamnus frangula L., from the bark of Rhamnus purshianus D.C. and from Aloe barbadensis Miller 
and/or various aloe species, mainly Aloe ferox Miller and its hybrids on the short-term alleviation of occasional 
constipation is well established. The Panel concludes that a cause and effect relationship has been established 
between consumption of hydroxyanthracene derivatives and improvement of bowel function.  
© European Food Safety Authority, 2013 
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Transitech
®
, hydroxyanthracene derivatives, bowel function, health claims 
                                                     
1 On request from the Competent Authority of France following an application by Vivatech, Question No EFSA-Q-2013-
00650, adopted on 09 October 2013. 
2 Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, 
Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna 
Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, 
Dominique Turck and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis 
Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Hildegard Przyrembel, Yolanda Sanz, Alfonso 
Siani, Anders Sjödin, Sean (J.J.) Strain, Inge Tetens, Hendrik Van Loveren, Hans Verhagen and Peter Willatts for the 
preparatory work on this scientific opinion. 
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SUMMARY 
Following an application from Vivatech, submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to hydroxyanthracene derivatives and improvement 
of bowel function. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is Transitech
®
, a food supplement which contains per 
tablet on average 226.8 mg powdered dried underground parts of Rheum palmatum L. and/or Rheum 
officinale Baillon and/or their hybrids standardised for hydroxyanthracene derivatives (2.2 to 2.76 %, 
5 mg/tablet), 38 mg of powdered dried root of Althaea officinalis L., 38 mg of powdered dried petals 
of Rosa centifolia L., 18 mg of powdered dried expressed juice from leaves of Cynara scolymus L. 
standardised for cynarine (2.5 %), 18 mg of powdered dried leaves of Ocimum basilicum L., 18 mg of 
powdered dried seeds of Coriandrum sativum L., 1.7x10
8
 CFU Saccharomyces cerevisiae 
UVAFERM SC (LYCC 6062), 4x10
6
 CFU Bifidobacterium longum R0175 and 4x10
6
 CFU 
Lactobacillus helveticus R0052. 
The Panel considers that the food, Transitech
®
, which is the subject of the claim, is sufficiently 
characterised. 
The claimed effect as proposed by the applicant is “improves bowel function”. The target population 
proposed by the applicant is the “general population experiencing disturbed defecation”. 
The Panel considers that an improvement of bowel function such as reduced transit time, more 
frequent bowel movements, increased faecal bulk, or softer stools is a beneficial physiological effect, 
provided that it does not result in diarrhoea. 
The applicant provided two unpublished randomised controlled trials as pertinent to the claim.  
One study had considerable methodological limitations, and no conclusions could be drawn from this 
study for the scientific substantiation of the claim. 
The second study was a randomised, placebo-controlled, double-blind study of parallel design which 
evaluated the effects of a daily consumption of Transitech
®
 vs. placebo over 10 days on stool 
frequency as the primary endpoint. Secondary outcomes included colonic transit time, stool size, stool 
consistency and bloating. The average number of daily stools was significantly higher in the 
intervention group compared to the control group, averaged over the 10 day intervention, and colonic 
transit time was significantly shorter in the intervention group than in the placebo group. Diarrhoea 
occurred in two subjects in the intervention group and one in the control group. 
The Panel notes the established effect of hydroxyanthracene derivatives from the root and rhizome of 
Rheum palmatum L. and/or Rheum officinale Baillon and/or their hybrids, but also from the leaves or 
fruits of Cassia senna L. and/or Cassia angustifolia Vahl, from the bark of Rhamnus frangula L., 
from the bark of Rhamnus purshianus D.C. and from Aloe barbadensis Miller and/or various aloe 
species, mainly Aloe ferox Miller and its hybrids, on the short-term alleviation of occasional 
constipation, at the proposed conditions of use (i.e. 10 mg per day), and the established mechanism by 
which hydroxyanthracene derivatives exert an effect on bowel function (i.e. stimulation of colonic 
motility, inhibition of absorption of water and electrolytes, and stimulation of secretion of water and 
electrolytes into the lumen of the colon resulting in enhanced concentrations of fluid and electrolytes 
in the lumen of the colon). 
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The Panel also notes that the available evidence does not establish that any of the other food 
constituents in Transitech
®
 exert an effect on bowel function. The Panel also notes that in the absence 
of a group consuming hydroxyanthracene derivatives alone in the studies submitted by the applicant, 
no conclusions can be drawn on whether Transitech
®
 exerts an effect on bowel function over and 
above an effect of hydroxyanthracene derivatives. The available evidence also does not establish that 
the combination of food constituents in Transitech
®
 would lead to a lower incidence of abdominal 
pain and passage of liquid stools which may be caused by the consumption of hydroxyanthracene 
derivatives, as claimed by the applicant.  
In weighing the evidence, the Panel took into account the established effect of hydroxyanthracene 
derivatives on bowel function, and that the mechanism by which hydroxyanthracene derivatives exert 
the effect is known. The Panel also took into account that the evidence provided by the applicant did 
not establish that any of the other food constituents in Transitech
®
 exert an effect on bowel function 
over and above the effect of hydroxyanthracene derivatives, or lead to a lower incidence of untoward 
effects of hydroxyanthracene derivatives. 
The Panel concludes that a cause and effect relationship has been established between consumption of 
hydroxyanthracene derivatives and improvement of bowel function. 
The Panel considers that the following wording reflects the scientific evidence: “Hydroxyanthracene 
derivatives improve bowel function”. 
The Panel considers that in order to bear the claim, a product should provide 10 mg 
hydroxyanthracene derivatives per day either from the root and rhizome of Rheum palmatum L. 
and/or Rheum officinale Baillon and/or their hybrids, and/or from the leaves or fruits of Cassia 
senna L. and/or Cassia angustifolia Vahl, and/or from the bark of Rhamnus frangula L and/or from 
the bark of Rhamnus purshianus D.C. and/or from Aloe barbadensis Miller and/or various aloe 
species, mainly Aloe ferox Miller and its hybrids. The target population is adults. 
In relation to the restrictions of use, the Panel notes that stimulant laxatives should not be consumed 
continually for periods longer than one to two weeks. The use of stimulant laxatives for more than 
two weeks requires medical supervision. Long-term use of stimulant laxatives should be avoided 
owing to the danger of electrolyte imbalance, impaired function of the intestine, and dependence on 
laxatives. Stimulant laxatives should only be used if an effect on bowel function cannot be achieved 
by a change of diet or the administration of bulk forming agents. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 02/07/2013. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 The scientific evaluation procedure started on 18/07/2013. 
 During its meeting on 09/10/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to 
hydroxyanthracene derivatives and improvement of bowel function. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: hydroxyanthracene derivatives 
and improvement of bowel function. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of hydroxyanthracene derivatives, a positive assessment of its safety, nor a decision on 
whether hydroxyanthracene derivatives are, or are not, classified as a foodstuff. It should be noted 
that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Vivatech, 8 rue Christophe Colomb, 75008 Paris, France. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 (Alexandre et al., 2011, unpublished). 
Food/constituent as stated by the applicant 
According to the applicant, the food which is the subject of the claim is “Transitech®”. Transitech® 
mainly contains rhubarb (226.8 mg per tablet), mallow (38 mg per tablet) and artichoke (18 mg per 
tablet) but also contains pale rose, basil, yeasts (Saccharomyces cerevisiae Uvaferm SC) and lactic 
ferments such as Bifidobacterium longum I-3470 (commercial name: Bifidobacterium Rosell-175) and 
Lactobacillus helveticus I-1722 (commercial name: Lactobacillus Rosell-52). 
Health relationship as claimed by the applicant 
According to the applicant, disturbed defecation and associated symptoms are very common issues in 
the general population. Re-establishing a normal and regular defecation (average of one stool per day 
in the general population) presents, according to the applicant, a psychological interest since it 
relieves from the gastro-intestinal symptoms and helps the subject to feel better.  
Wording of the health claim as proposed by the applicant 
The following wording is proposed by the applicant: “Improves bowel function”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the recommended daily amount for this product is two pills per day, 
representing 453 mg of rhubarb, including 10 mg of “anthracene” derivatives. The supplementation 
should be taken over 10 days. The target population is the general population experiencing disturbed 
defecation.  
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is Transitech
®
, a food supplement which contains per 
tablet on average 226.8 mg powdered dried underground parts of Rheum palmatum L. and/or Rheum 
officinale Baillon and/or their hybrids standardised for hydroxyanthracene derivatives (2.2 to 2.76 %, 
5 mg/tablet), 38 mg of powdered dried root of Althaea officinalis L., 38 mg of powdered dried petals 
of Rosa centifolia L., 18 mg of powdered dried expressed juice from leaves of Cynara scolymus L. 
standardised for cynarine (2.5 %), 18 mg of powdered dried leaves of Ocimum basilicum L., 18 mg of 
powdered dried seeds of Coriandrum sativum L., 1.7x10
8
 CFU Saccharomyces cerevisiae 
UVAFERM SC (LYCC 6062), 4x10
6
 CFU Bifidobacterium longum R0175 and 4x10
6
 CFU 
Lactobacillus helveticus R0052. 
The applicant provided information on the batch-to-batch variability with respect to the 
hydroxyanthracene derivative content of the powdered dried underground parts of Rheum 
palmatum L. and/or Rheum officinale Baillon and/or their hybrids, as well as with respect to the 
cynarine content of the dried expressed juice from leaves of Cynara scolymus L. used in Transitech
®
. 
The applicant also provided a certificate of analysis of the hydroxyanthracene derivative and cynarine 
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content of one batch of Transitech
®
. The applicant indicated that all ingredients of plant origin met 
the requirements set out in the European Pharmacopoeia monographs. 
The strain B. longum R0175 is also known as B. longum subsp. longum CNCM I-3470. A culture 
collection number from the Collection Nationale de Cultures de Microorganismes (CNCM I-3470) 
has been provided. The CNCM is a restricted-access non-public collection which has the status of an 
International Depositary Authority under the Budapest Treaty. Data on the identification and 
characterisation of B. longum subsp. longum CNCM I-3470 at species and strain level were 
considered in an earlier opinion of the Panel (EFSA NDA Panel, 2012), where it was concluded that 
the strain B. longum subsp. longum CNCM I-3470 was sufficiently characterised. 
The strain L. helveticus R0052 is also known as L. helveticus CNCM I-1722. A culture collection 
number from the Collection Nationale de Cultures de Microorganismes (CNCM I-1722) has been 
provided. Data on the identification and characterisation of L. helveticus CNCM I-1722 at species and 
strain level were considered in an earlier opinion of the Panel (EFSA NDA Panel, 2012), where it was 
concluded that the strain L. helveticus CNCM I-1722 was sufficiently characterised. 
Data on the identification and characterisation of Saccharomyces cerevisiae UVAFERM SC (LYCC 
6062) at species and strain level, by using genotypic (sequencing analysis of the D2 domain of 26S 
rDNA and RAPD) methods, were provided. The Panel considers that Saccharomyces cerevisiae 
UVAFERM SC (LYCC 6062) is sufficiently characterised. 
The applicant indicated that the constituents in Transitech
®
 responsible for the claimed effect are 
hydroxyanthracene derivatives derived from Rheum palmatum L. and/or Rheum officinale Baillon 
and/or their hybrids, and fructo-oligosaccharides derived from Althaea officinalis L. and Cynara 
scolymus L. The applicant also indicated that other ingredients in Transitech
®
 are added in order to 
prevent bloating, flatulence and spasms. 
The Panel considers that the food, Transitech
®
, which is the subject of the claim, is sufficiently 
characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect as proposed by the applicant is “improves bowel function”. The target population 
proposed by the applicant is the “general population experiencing disturbed defecation”. 
The Panel considers that an improvement of bowel function such as reduced transit time, more 
frequent bowel movements, increased faecal bulk, or softer stools is a beneficial physiological effect, 
provided that it does not result in diarrhoea. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in “PubMed” with the search terms [“rhubarb” OR 
“rheum palmatum” OR “rheum officinale” OR “sennosides” OR “senna” OR “artichoke” OR “yeast” 
OR “Saccharomyces cerevisiae” OR “Bifidobacterium longum” OR “Lactobacillus helveticus”] AND 
[“constipation” OR “defecation” OR “transit time” OR “colonic motility”]. No limits were applied in 
the search. The time span which was covered by the search was not indicated. Inclusion criteria were 
clinical studies performed with Transitech
®
, and exclusion criteria were studies in patients with 
gastro-intestinal pathology. The Panel notes the limitations in the literature search performed. 
The applicant indicated that no pertinent human study was identified through this literature search. 
The applicant provided two unpublished randomised controlled trials (RCTs) (Guillou and Chesne 
2000; Alexandre et al. 2011) as pertinent to the claim. These two RCTs were performed with 
Transitech
®
.  
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The study by Guillou and Chesne (2000, unpublished) was a double-blind RCT with a cross-over 
design in 33 women (baseline characteristics not given), of whom only 15 completed both study 
periods and were included in the analysis. Each product (Transitech® or placebo (lactose)) was tested 
for two eight-day periods with a seven day wash-out period in between. Statistical analysis was 
carried out using the paired t-test.  
The Panel notes the high drop-out rate, that no information is available on whether stool frequency 
returned to baseline after the wash-out period, and the limitations of the paired t-test in the analysis of 
cross-over designs when potential carry-over or period effects cannot be excluded. The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim. 
The study by Alexandre et al. (2011, unpublished, claimed as proprietary) was a randomised, placebo-
controlled, double-blind study of parallel design which evaluated the effects of a daily consumption of 
Transitech
®
 vs. placebo (sugar cane, magnesium stearate) over 10 days after a seven-day run-in period 
on stool frequency as the primary endpoint in subjects presenting with two to five stools per week. 
Secondary outcomes included colonic transit time, stool size, stool consistency and bloating.  
One-hundred healthy adults with an average of 0.56 ± 0.21 daily stools were randomised in blocks of 
four to consume either two tablets of Transitech
®
 (n = 50) or placebo (n = 50). The study was 
powered (β = 0.1) to detect a difference between groups at a significance level of 0.05, assuming a 
variation of 30 %, and 8 % loss to follow-up. Stool frequency, stool size, consistency and bloating 
(latter three evaluated on five-score scales) were recorded daily in self-administered questionnaires 
from day minus six to day ten. Segmental colonic transit times were assessed at day zero and day ten 
by abdominal X-rays using radiopaque markers. The Panel notes that no information was provided by 
the applicant on the validation of the scale used to assess stool consistency, stool size and bloating.  
Subjects were instructed not to modify their eating habits. Six subjects (three per group) did not 
complete the study. No baseline data were available for these subjects, and they were not considered 
in the analysis. Ten of the included subjects had a normal stool frequency with more than five stools 
per week. Data were averaged over time, and analysed using the unpaired t-test to compare the 
difference in percent change from baseline in frequency of defecations between the intervention and 
control group, and using analysis of covariance (ANCOVA) with baseline measures as covariate for 
analysis of absolute values for all endpoints.  
The average number of daily stools was significantly higher in the intervention group compared to the 
control group, averaged over the 10 day intervention (mean ± SD: 0.95 ± 0.49 (intervention) vs. 
0.66 ± 0.22 (control); p < 0.001) using ANCOVA. Also at day 10, total colonic transit time (mean 
hours ± SD 33.79 ± 28.19 (intervention) vs. 56.38 ± 36.16 (control); p = 0.01) was significantly 
shorter in the intervention group than in the placebo group. 
Diarrhoea occurred in two subjects in the intervention group and one in the control group. 
The Panel considers that this study shows an effect of Transitech
®
 on bowel function by a decrease in 
colonic transit time and an increase in stool frequency. 
The Panel notes the established effect of hydroxyanthracene derivatives from the root and rhizome of 
Rheum palmatum L. and/or Rheum officinale Baillon and/or their hybrids, but also from the leaves or 
fruits of Cassia senna L. and/or Cassia angustifolia Vahl, from the bark of Rhamnus frangula L., 
from the bark of Rhamnus purshianus D.C. and from Aloe barbadensis Miller and/or various aloe 
species, mainly Aloe ferox Miller and its hybrids, on the short-term alleviation of occasional 
constipation at the proposed conditions of use (i.e. 10 mg per day), and the established mechanism by 
which hydroxyanthracene derivatives exert an effect on bowel function (i.e. stimulation of colonic 
motility, inhibition of absorption of water and electrolytes, and stimulation of secretion of water and 
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electrolytes into the lumen of the colon resulting in enhanced concentrations of fluid and electrolytes 
in the lumen of the colon) (WHO, 1999, 2004; HMPC, 2006a, 2006b, 2006c, 2006d, 2007a, 2007b, 
2008). 
The Panel notes that the available evidence does not establish that any of the other food constituents 
in Transitech
®
 exert an effect on bowel function. The Panel also notes that in the absence of a group 
consuming hydroxyanthracene derivatives alone in the studies submitted by the applicant, no 
conclusions can be drawn on whether Transitech
®
 exerts an effect on bowel function over and above 
an effect of hydroxyanthracene derivatives. The available evidence also does not establish that the 
combination of food constituents in Transitech
®
 would lead to a lower incidence of abdominal pain 
and passage of liquid stools which may be caused by the consumption of hydroxyanthracene 
derivatives (WHO, 1999, 2004; HMPC, 2006a, 2006b, 2006c, 2006d, 2007a, 2007b, 2008), as 
claimed by the applicant.  
In weighing the evidence, the Panel took into account the established effect of hydroxyanthracene 
derivatives on bowel function, and that the mechanism by which hydroxyanthracene derivatives exert 
the effect is known. The Panel also took into account that the evidence provided by the applicant did 
not establish that any of the other food constituents in Transitech
®
 exert an effect on bowel function 
over and above the effect of hydroxyanthracene derivatives, or lead to a lower incidence of untoward 
effects of hydroxyanthracene derivatives. 
The Panel concludes that a cause and effect relationship has been established between consumption of 
hydroxyanthracene derivatives and improvement of bowel function. 
On the basis of the published literature on hydroxyanthracene derivatives, the Panel could have 
reached its conclusions without the human intervention study claimed as proprietary by the applicant 
(Alexandre et al., 2011, unpublished). 
4. Panel’s comments on the proposed wording 
The Panel considers that the following wording reflects the scientific evidence: “Hydroxyanthracene 
derivatives improve bowel function.” 
5. Conditions and restrictions of use  
The Panel considers that in order to bear the claim, a product should provide 10 mg 
hydroxyanthracene derivatives per day either from the root and rhizome of Rheum palmatum L. 
and/or Rheum officinale Baillon and/or their hybrids, and/or from the leaves or fruits of Cassia 
senna L. and/or Cassia angustifolia Vahl, and/or from the bark of Rhamnus frangula L and/or from 
the bark of Rhmanus purshianus D.C. and/or from Aloe barbadensis Miller and/or various aloe 
species, mainly Aloe ferox Miller and its hybrids. The target population is adults.  
In relation to the restrictions of use, the Panel notes that stimulant laxatives should not be consumed 
continually for periods longer than one to two weeks. The use of stimulant laxatives for more than 
two weeks requires medical supervision. Long-term use of stimulant laxatives should be avoided 
owing to the danger of electrolyte imbalance, impaired function of the intestine, and dependence on 
laxatives. Stimulant laxatives should only be used if an effect on bowel function cannot be achieved 
by a change of diet or the administration of bulk forming agents (WHO, 1999, 2004; HMPC, 2006a, 
2006b, 2006c, 2006d, 2007a, 2007b, 2008).  
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, Transitech®, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect proposed by the applicant is “improves bowel function”. The target 
population proposed by the applicant is “the general population experiencing disturbed 
defecation“. An improvement of bowel function such as reduced transit time, more frequent 
bowel movements, increased faecal bulk, or softer stools is a beneficial physiological effect, 
provided that it does not result in diarrhoea. 
 A cause and effect relationship has been established between consumption of 
hydroxyanthracene derivatives and improvement of bowel function. 
 The following wording reflects the scientific evidence: “Hydroxyanthracene derivatives 
improve bowel function”. 
 In order to bear the claim, a product should provide 10 mg hydroxyanthracene derivatives per 
day either from the root and rhizome of Rheum palmatum L. and/or Rheum officinale Baillon 
and/or their hybrids, and/or from the leaves or fruits of Cassia senna L. and/or Cassia 
angustifolia Vahl, and/or from the bark of Rhamnus frangula L and/or from the bark of 
Rhamnus purshianus D.C. and/or from Aloe barbadensis Miller and/or various aloe species, 
mainly Aloe ferox Miller and its hybrids. The target population is adults. 
 In relation to the restrictions of use, it is noted that stimulant laxatives should not be 
consumed continually for periods longer than one to two weeks. The use of stimulant 
laxatives for more than two weeks requires medical supervision. Long-term use of stimulant 
laxatives should be avoided owing to the danger of electrolyte imbalance, impaired function 
of the intestine, and dependence on laxatives. Stimulant laxatives should only be used if an 
effect on bowel function cannot be achieved by a change of diet or the administration of bulk 
forming agents. 
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ABBREVIATIONS 
ANCOVA  Analysis of covariance 
CFU  Colony forming units 
CNCM  Collection Nationale de Cultures de Microorganismes 
RAPD  Random amplified polymorphic deoxyribonucleic acid 
RCT   Randomised controlled trials 
rDNA  Ribosomal deoxyribonucleic acid 
